Sanofi Aventis (SNY) - Company Value to Net Income

Corporate emblem and logo of Sanofi SA (SNY)

The P/E ratio of the issuer reflects the market valuation dynamics of Sanofi (SNY), where 25.30 serves as the current level of the metric. The growth model is based on a transition from costly research to the profitable production of mass-market drugs. Pharmacy supply efficiency is sustained through a global distribution network. Meanwhile, leadership in the therapy of immune pathologies allows the behemoth to successfully withstand market pressure.

SNY sanofi.com: Price to Earnings Ratio in the range 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Sanofi Aventis (SNY)

- share price and expert price forecast:
Price Performance Chart sanofi.com|SNY - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Sanofi S.A.|SNY - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Sanofi|SNY - Company Book Value|Market Value to Book Value Ratio sanofi.com|SNY - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Ratio Sanofi|SNY - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Sanofi Group|SNY - Company Debts|Debt to Book Value Ratio Sanofi S.A.|SNY - Company Long-Term Debts|Short-Term Indebtedness Sanofi|Interim Coverage Ratio sanofi.com
- business earnings and investment ratios data:
SNY - Net Profit|Projected Future Earnings Sanofi|SNY - Price to Earnings Ratio|Price to Future Earnings Ratio Sanofi SA|SNY - Price/Earnings to Growth Ratio|Company Value to EBITDA Sanofi S.A.|SNY - Operating profit EBITDA|Earnings per one share for the last 12 months Sanofi|SNY - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months sanofi.com|SNY - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Sanofi
Comprehensive company analysis:sanofi.com SNY
Product sample of Sanofi

Sanofi (SNY), under the leadership of Paul Hudson, is transforming its structure by focusing on its immunology portfolio and spinning off its consumer healthcare segment. The P/E ratio relates current market capitalization to net income, determining the cost of one dollar of earnings. This metric allows an investor to assess the premium paid for the asset and the risk of liquidity shortages during macroeconomic shocks. Analyzing the market valuation via the P/E ratio helps identify anomalies in the company's value in a timely manner.

Key competitors

LLY: Company Value to Net Income|P/E Multiple ABBV|AZN (AstraZeneca Plc) - Company Value to Net Income|Price to Earnings Ratio Novartis Inc. NVS|MSD (MRK) - Market Cap to Earnings|NVO - Price to Earnings Ratio|AMGN: Price to Earnings Ratio|PFE: P/E Multiple|Price to Earnings Multiple BMY|GSK (GlaxoSmithKline plc) - P/E Multiple|Takeda Pharma (TAK) - Business Payback Period|Price to Earnings Ratio Teva (TEVA)|drreddys.com - Price to Earnings Multiple|P/E Multiple VTRS (Viatris)|Market Cap to Net Income Ratio Roivant|ZLAB - Price to Earnings Ratio|Business Payback Period Bausch Health Corp BHC|COSM: P/E Multiple